---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-26-000906"
form_type: "8-K"
ticker: "ADMA"
cik: "0001368514"
company_name: "ADMA BIOLOGICS, INC."
filed_at: "2026-01-12T23:59:59+00:00"
generated_at: "2026-05-16T10:48:44.384764+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# ADMA prelim FY2025 rev ~$510-511M, raises FY2026 rev/EBITDA guidance, targets >$1.1B by 2029

## Summary
- Preliminary FY2025 total revenue ~$510-511M, meeting or exceeding prior guidance. Cash grew to ~$88M with ~$40M Q4 operating cash flow.
- FY2026 revenue guidance raised to ~$635M (from $630M); FY2026 adjusted EBITDA raised to ~$360M (from $355M). Adjusted net income reiterated at ~$255M.
- FY2027 revenue guided ~$775M, adjusted net income ~$315M, adjusted EBITDA ~$455M.
- Long-term targets: >$1.1B revenue and >$700M adjusted EBITDA by FY2029. Yield-enhanced production now routine, 2026 first full year of monetization.
- Divested three plasma centers for $12M, secured long-term supply agreements, expects accretive cost savings from strategic repositioning.

## SEC filing metadata
- accession: 0001140361-26-000906
- form_type: 8-K
- ticker: ADMA
- cik: 0001368514
- company_name: ADMA BIOLOGICS, INC.
- filed_at: 2026-01-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1368514/000114036126000906/0001140361-26-000906-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1368514/000114036126000906/ef20062685_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-26-000906
- JSON: https://secwatch.observer/filing/0001140361-26-000906.json
- Plain text: https://secwatch.observer/filing/0001140361-26-000906.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.